These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20466286)

  • 1. Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
    Chen CP
    Taiwan J Obstet Gynecol; 2010 Mar; 49(1):3-12. PubMed ID: 20466286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
    Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
    Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
    Nicolaides KH
    Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the ductus venosus, tricuspid blood flow and the nasal bone in second-trimester screening for trisomy 21.
    Stressig R; Kozlowski P; Froehlich S; Siegmann HJ; Hammer R; Blumenstock G; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Apr; 37(4):444-9. PubMed ID: 20645398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of combined detailed first-trimester ultrasound-biochemical analysis for screening fetal aneuploidy in the era of non-invasive prenatal testing.
    Ye C; Duan H; Liu M; Liu J; Xiang J; Yin Y; Zhou Q; Yang D; Yan R; Li R
    Arch Gynecol Obstet; 2024 Aug; 310(2):843-853. PubMed ID: 37938359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester.
    Geipel A; Willruth A; Vieten J; Gembruch U; Berg C
    Ultrasound Obstet Gynecol; 2010 May; 35(5):535-9. PubMed ID: 20183867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
    Kagan KO; Valencia C; Livanos P; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jan; 33(1):18-22. PubMed ID: 19031473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fetal hepatic artery flow assessment in prenatal diagnostics--a review of the literature].
    Lipa M; Samaha RB; Borowski D; Wielgoś M; Wegrzyn P
    Ginekol Pol; 2014 Jul; 85(7):532-5. PubMed ID: 25118506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended first-trimester screening using multiple sonographic markers and maternal serum biochemistry: a five-year prospective study.
    Hsiao CH; Cheng PJ; Shaw SW; Hsu JJ; Chen RC; Tseng YJ; Chu WC
    Fetal Diagn Ther; 2014; 35(4):296-301. PubMed ID: 24503519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of fetal maxillary length in the first trimester screening for trisomy 21.
    Unsal N; Ozat M; Kanat-Pektas M; Gungor T; Danisman N
    Arch Gynecol Obstet; 2011 Jun; 283(6):1199-205. PubMed ID: 20505946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.